Topics
-
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
-
Business Results Announcement for the First Three Months of the Fiscal Year Ending March 31, 2022 (See Latest Financial Statements)
-
Undertaking the Never-Ending Mission of “Creating a Stable Supply of Reagents”
-
Sysmex Selected for Inclusion in All ESG Indices adopted by the GPIF for Several Years
-
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval
-
Introducing "Sysmex Smart Work" to Promote Work Style Reform under the “New Normal”
Press Releases
- Notice Concerning Absorption-Type Merger (Simplified/Short-Form Merger) of Wholly Owned Subsidiary (PDF：234KB)
- Approval of "Genetic Diagnosis and Counseling for Inherited Retinal Dystrophy" Using Gene Panel Testing System for Advanced Medical Care B (PDF：202KB)
- Information about Judgment of the Litigation against Sysmex Corporation and its Subsidiary (PDF：132KB)
- Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2022
- Sysmex Forms Strategic Alliance with QIAGEN for Providing Global Cancer Companion Diagnostics that Uses Ultra-sensitive Liquid Biopsy NGS Technology (PDF：205KB)
